06.09.18: Roadshow London
Roadshow LondonLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 5, 2018 Category: Pharmaceuticals Source Type: news
30.07.19: Q2 2019 Interim Report
Q2 2019 Interim ReportLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 5, 2018 Category: Pharmaceuticals Source Type: news
30.10.19: Q3 2019 Interim Report
Q3 2019 Interim ReportLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 5, 2018 Category: Pharmaceuticals Source Type: news
05.09.18: Second quarter of 2018
Bayer completes biggest acquisition in its historyMonsanto business included on prorated basis from June 7 / Group sales advance by 8.5 percent (Fx & portfolio adj.) to 9.481 billion euros / EBITDA before special items increases by 3.9 percent to 2.335 billion euros despite unfavorable currency effects / Pharmaceuticals registers higher sales (Fx & portfolio adj.) but lower earnings - substantial increase in R&D investment / Consumer Health business weak again / Crop Science achieves strong increase in sales and earnings after weak prior-year quarter / Animal Health improves sales (Fx & portfolio adj.) and earnings / Net i...
Source: Bayer IR Newsfeed: Events - September 5, 2018 Category: Pharmaceuticals Source Type: news
04.09.18: LEO Pharma closes acquisition of Bayer's prescription dermatology business in the United States
LEO Pharma closes acquisition of Bayer's prescription dermatology business in the United Statesmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 4, 2018 Category: Pharmaceuticals Source Type: news
03.09.18: Brazilian court rules that growers will continue to have access to glyphosate
Brazilian court rules that growers will continue to have access to glyphosatemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 3, 2018 Category: Pharmaceuticals Source Type: news
30.08.18: Not intended for U.S. and UK Media
Bayer receives US approval for modern hemophilia A treatment Jivi® with a step-wise prophylaxis dosing regimenJivi's extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and further individually adjusted to less or more frequent dosingmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 30, 2018 Category: Pharmaceuticals Source Type: news
27.08.18: New data presented at ESC Congress 2018:
Results of COMMANDER HF and MARINER studies with rivaroxaban published Studies in very sick patient populations reaffirm and further strengthen the safety profile of rivaroxaban / Study results did not show a statistical difference in primary endpoints / COMMANDER HF study evaluated rivaroxaban in patients following an acute decompensation of heart failure and concomitant coronary artery disease / MARINER study evaluated rivaroxaban in acutely medically ill patientsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 27, 2018 Category: Pharmaceuticals Source Type: news
27.08.18: Not intended for U.S. and UK Media
Bayer submits European marketing authorization application for larotrectinib for the treatment of TRK fusion cancermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 26, 2018 Category: Pharmaceuticals Source Type: news
24.08.18: Not intended for U.S. and UK Media
Bayer secures approval in the EU for Xarelto® (rivaroxaban) for patients with coronary or peripheral artery diseaseXarelto is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in patients with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events / Launch first expected in Germanymehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 24, 2018 Category: Pharmaceuticals Source Type: news
05.09.18: Q2 2018 Investor Conference Call
Q2 2018 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 22, 2018 Category: Pharmaceuticals Source Type: news
20.08.18: Decision by Hamburg Regional Court in respect of reporting by WirtschaftsWoche
Decision by Hamburg Regional Court in respect of reporting by WirtschaftsWochemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 21, 2018 Category: Pharmaceuticals Source Type: news
20.08.18:
mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 20, 2018 Category: Pharmaceuticals Source Type: news
20.08.18: Decision by Hamburg Regional Court in respect of reporting by WirtschaftsWoche
Decision by Hamburg Regional Court in respect of reporting by WirtschaftsWochemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 19, 2018 Category: Pharmaceuticals Source Type: news
23.08.18: Conference Call on Glyphosate Litigation
Conference Call on Glyphosate LitigationLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 19, 2018 Category: Pharmaceuticals Source Type: news
